These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30997878)

  • 1. An exceptional group of non-small cell lung cancer difficult to diagnose: Evaluation of lipid-poor adrenal lesions.
    Simsek FS; Arslan M; Dag Y
    Bosn J Basic Med Sci; 2019 May; 19(2):195-200. PubMed ID: 30997878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is FDG-PET/CT used correctly in the combined approach for nodal staging in NSCLC patients?
    Simsek FS; Comak A; Asik M; Kuslu D; Balci TA; Ulutas H; Koroglu R; Kekilli E; Akatli A; Elmali F; Yalcin NC; Akyol H
    Niger J Clin Pract; 2020 Jun; 23(6):842-847. PubMed ID: 32525121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET/CT features discriminate risk of metastasis among single-bone FDG lesions detected in newly diagnosed non-small-cell lung cancer patients.
    Lim CH; Ahn TR; Moon SH; Cho YS; Choi JY; Kim BT; Lee KH
    Eur Radiol; 2019 Apr; 29(4):1903-1911. PubMed ID: 30315418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of nodal involvement in non-small-cell lung cancer with 18F-FDG-PET/CT: mediastinal blood pool cut-off has the highest sensitivity and tumour SUVmax/2 has the highest specificity.
    Mallorie A; Goldring J; Patel A; Lim E; Wagner T
    Nucl Med Commun; 2017 Aug; 38(8):715-719. PubMed ID: 28658052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of different
    Anwar H; Vogl TJ; Abougabal MA; Grünwald F; Kleine P; Elrefaie S; Nour-Eldin NA
    Ann Nucl Med; 2018 Dec; 32(10):687-694. PubMed ID: 30219989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients.
    Herbrik M; Treffert J; Geiger B; Riegger C; Hartung V; Rosenbaum-Krumme SJ; Forsting M; Antoch G; Heusner TA
    J Nucl Med; 2011 Oct; 52(10):1520-5. PubMed ID: 21908390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.
    Ghaly G; Rahouma M; Kamel MK; Nasar A; Harrison S; Nguyen AB; Port J; Stiles BM; Altorki NK; Lee PC
    Ann Thorac Surg; 2017 Oct; 104(4):1153-1158. PubMed ID: 28551047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of 18F-FDG-positron emission tomography in presurgical evaluation of nonspecific or suspectious adrenal masses in non-oncologic patients].
    Pavón-Paz I; Rosado-Sierra JA; Balsa-Bretón MÁ; Guijarro-Armas G; Merino-Viveros M; Penín-Gonzalez FJ
    Med Clin (Barc); 2016 Feb; 146(3):104-7. PubMed ID: 26343158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of maximum standardized uptake value with occult mediastinal lymph node metastases in cN0 non-small cell lung cancer.
    Lin JT; Yang XN; Zhong WZ; Liao RQ; Dong S; Nie Q; Weng SX; Fang XJ; Zheng JY; Wu YL
    Eur J Cardiothorac Surg; 2016 Nov; 50(5):914-919. PubMed ID: 27113090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients.
    Lu Y; Xie D; Huang W; Gong H; Yu J
    Neoplasma; 2010; 57(2):129-34. PubMed ID: 20099976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorodeoxyglucose-positron-emission tomography/computed tomography imaging for adrenal masses in patients with lung cancer: review and diagnostic algorithm.
    Stone WZ; Wymer DC; Canales BK
    J Endourol; 2014 Jan; 28(1):104-11. PubMed ID: 23927734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative 18F-FDG SUVmax >6.3 or Size >2.3 cm of primary lesions predict lymph nodes metastasis with higher negative predictive value in peripheral cT1 non-small-cell lung cancer.
    Li XF; Shi YM; Niu R; Yang YS; Shao XN; Wang JF; Shao XL; Zhang FF; Xue XQ; Wang YT
    Nucl Med Commun; 2021 Dec; 42(12):1328-1335. PubMed ID: 34284441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm.
    Brady MJ; Thomas J; Wong TZ; Franklin KM; Ho LM; Paulson EK
    Radiology; 2009 Feb; 250(2):523-30. PubMed ID: 19188319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.